In Vitro Characterization of Human CD24 hi CD38 hi Regulatory B Cells Shows CD9 Is Not a Stable Breg Cell Marker.
Mohd Jaya FN., Garcia SG., Borras FE., Guerrero D., Chan GCF., Franquesa M.
Laboratory Study on Face & Skin, published in Int J Mol Sci (2021) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Int J Mol Sci (2021)
- Country
- Switzerland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 33925530
- DOI
- 10.3390/ijms22094583
Abstract (original English)
Regulatory B (Breg) cells are endowed with immune suppressive functions. Various human and murine Breg subtypes have been reported. While interleukin (IL)-10 intracellular staining remains the most reliable way to identify Breg cells, this technique hinders further essential functional studies. Recent findings suggest that CD9 is an effective surface marker of murine IL-10 competent Breg cells. However, the stability of CD9 and its relevance as a unique marker for human Breg cells, which have been widely characterized as CD24 hi CD38 hi , have not been investigated. Here, we demonstrate that CD9 expression is sensitive to in vitro B cell stimulations. CD9 expression could either be re-expressed or downregulated in purified CD9-negative B cells and CD9-positive B cells, respectively. We found no significant differences in the Breg differentiation capacity of the CD9-negative and CD9-positive B cells. Furthermore, CD9-positive B cells co-express CD40 and CD86, suggesting their nature as B cell activation or co-stimulatory molecules, rather than regulatory ones. Therefore, we report the relatively unstable CD9 as a distinct surface molecule, indicating the need for further research for a more reliable marker to purify human Breg cells.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Oncologic safety of autologous fat grafting in head and neck cancer patients: A scoping review.
Systematic Review with a reported sample of 116 on Face & Skin, published in Med Oral Patol Oral Cir Bucal (2026) — summary generated from the PubMed abstract.
- 2026
- n = 116
Med Oral Patol Oral Cir Bucal - Level ASystematic ReviewEurope PMC
Stem cell-derived exosomes in tissue regeneration of oral and maxillofacial region: A systematic review
Systematic Review on Chronic Wound, published in Medicine (Baltimore) (2026) — summary generated from the PubMed abstract.
- 2026
Medicine (Baltimore) - Level AMeta-analysisPubMed
Stromal Vascular Fraction-Assisted Fat Grafting: A Systematic Review and Meta-analysis of Clinical Outcomes.
Meta-analysis on Face & Skin, published in Aesthetic Plast Surg (2026) — summary generated from the PubMed abstract.
- 2026
Aesthetic Plast Surg - Level ASystematic ReviewEurope PMC
Applications of Exosomes in Female Medicine: A Systematic Review of Molecular Biology, Diagnostic and Therapeutic Perspectives
Systematic Review on Face & Skin, Systemic / IV, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci2 citations - Level ASystematic ReviewPubMed
The use of cellular therapies for trigeminal neuralgia: a systematic review of behavioral and molecular outcomes.
Systematic Review with a reported sample of 8 on Neuroinflammation, published in Neurosurg Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 8
Neurosurg Rev - Level ASystematic ReviewEurope PMC
Osteogenic and Biocompatibility Potential of Polylactic Acid-Based Materials: A Systematic Review of Human Primary Cells Studies
Systematic Review on Face & Skin, published in J Funct Biomater (2026) — summary generated from the PubMed abstract.
- 2026
J Funct Biomater